

## REMARKS

Claims 1-44 were pending in the application and subject to a restriction requirement. Specifically, the Office Action has identified the following groups:

- I. Claims 1-21, drawn to methods for treating cancer, classified in class 514, subclass 34+.
- II. Claims 22-44, drawn to compositions, classified in class 424, subclass 603.

Applicants hereby elect the invention of Group II claims 22-44. The election is made without traverse. The non-elected claims have been canceled.

Applicants have amended the claims to correct minor topographical errors. No new matter is added by these changes.

## CONCLUSION

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made".

Enclosed is a check in the amount of \$55.00 and a petition to extend the period for replying for one month, to and including May 28, 2002, since May 27<sup>th</sup> falls on a federal holiday.


If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: May 28, 2002

for Dean Elman (Reg. No. 12,506)  
Paul T. Clark  
Reg. No. 30,162

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045



**“Version with markings to show changes made”**

**In the Claims:**

Claims 1-21, have been canceled without prejudice.

Claims 24, 26, and 36 have been amended as follows:

24. (Amended) The composition of claim 22, wherein the anticancer agent is selected from the group consisting of methotrexate, [cis-platin] cisplatin, prednisone, hydroxyprogesterone, [medroxyprogesterone] medroxyprogesterone acetate, megestrol acetate, diethylstilbestrol, testosterone propionate, fluoxymesterone, vinblastine, vincristine, vindesine, daunorubicin, doxorubicin, hydroxyurea, procarbazine, aminogluthetamide, mechlorethamine, cyclophosphamide, [mephalan] melfalan, uracil mustard, chlorambucil, busulfan, carmustine, [lomusline] lomustine, dacarbazine (DTIC, dimethyltriazenomideazolecarboxamide), procarbazine, [fluorouracil] 5-fluorouracil, cytarabine, cytosine [arabinoxide] arabinoside, [mercaptopurine,] [6-mercaptopurine] 6-mercaptopurine, [tamoxifan,] tamoxifen, paclitaxel, [etoposide,] etoposide, vinorelbine, gemcitabine, leuprolide, flutamide, [goserelin] goserelin acetate, [and] thioguanine, their derivatives and mixtures thereof.

26. (Amended) The composition of claim 22, wherein the nanocrystalline or poorly crystalline calcium phosphate cement comprises a calcium phosphate selected from the group consisting of amorphous

calcium phosphate, poorly crystalline apatitic (PCA) calcium phosphates [(PCA)], dicalcium phosphates, such as dicalcium phosphate dihydrate (DCPD) and dicalcium phosphate anhydrous (DCPA), tricalcium phosphates (TCP), monetite, monocalcium phosphate monohydrate (MCPM), [hetpacalcium] ~~heptacalcium~~ phosphate, calcium pyrophosphate, calcium metaphosphate, octacalcium phosphates (OCP), hydroxyapatites (HA).

36. (Amended) The composition of claim 22, wherein a therapeutically [effect] effective amount of anticancer agent is released from the composition for a time greater than two [week] weeks.